# Demographic and topographic findings suggesting poor response to crosslinking-iontophoresis in patients with progressive keratoconus

## TL;DR

This study found that I-CXL treatment for keratoconus may not effectively stop progression, especially in younger patients and those with a family history of the condition.

## Contribution

The study identifies demographic and topographic factors predicting poor response to I-CXL in progressive keratoconus.

## Key findings

- I-CXL did not effectively stop keratoconus progression in most variables two years post-treatment.
- Patients under 19 years and those with a family history of corneal ectasia showed worse outcomes.
- Phenotypes 3 and 4 were associated with progression after I-CXL.

## Abstract

To evaluate demographic and tomographical parameters in predicting treatment response following transepithelial iontophoresis-assisted corneal cross-linking (I-CXL) for progressive keratoconus.

Forty eyes (20 aged < 19 years and 20 aged ≥ 19 years) underwent I-CXL treatment between 2016 and 2022. Progression criteria based on the ABCD system, changes in asphericity (Q), demographic factors and keratoconus phenotypes were evaluated. Subjects were followed for 24 months after procedure.

Sixty percent of participants were male. The mean age at the time of treatment was 21.0 ± 6.0 years. All tomographical values showed progression after 2 years of follow-up (p < 0.05), particularly during the first 6 months, except for anterior curvature. Within the ABCD grading system, we observed: A) an increase in anterior curvature, more evident with lower initial values; B) an increase in posterior curvature, more pronounced with higher initial values. Two years after I-CXL, 20% of subjects met progression criteria in two or more parameters, with 62.5% being under 19 years of age. Patients with a family history of corneal ectasia exhibited a mean KMax progression of 1.94D ± 1.88, (p = 0.046). Only phenotypes 3 and 4 showed progression. Although patients under 19 years showed greater progression in all tomographical variables at the end of the study, this difference was not statistically significant.

Treatment with I-CXL did not stop progression in the variables studied two years after the procedure in an effective manner, especially in patients younger than 19 years. A family history of corneal ectasia and subtype 4 keratoconus predicted a less favourable response to I-CXL.